Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Politics for Pros- moderated -- Ignore unavailable to you. Want to Upgrade?

To: i-node who wrote (754508)	12/30/2021 10:25:02 PM
From: kckip	10 Recommendations Recommended By D. Long Hugh Bett i-node isopatch lightshipsailor and 5 more members Read Replies (1) \| Respond to of 794008

Here is the specific criterion Dr. Carson references in the FDA guidance doc....we can probably debate long and loud whether we agree all applicable criteria are met for these inoculations and CV-19 <g>. fda.gov d. No Alternatives For FDA to issue an EUA, there must be no adequate, approved, and available alternative to the candidate product for diagnosing, preventing, or treating the disease or condition. A potential alternative product may be considered “unavailable” if there are insufficient supplies of the approved alternative to fully meet the emergency need. A potential alternative product may be considered "inadequate" if, for example, there are contraindicating data for special circumstances or populations (e.g., children, immunocompromised individuals, or individuals with a drug allergy), if a dosage form of an approved product is inappropriate for use in a special population (e.g., a tablet for individuals who cannot swallow pills), or if the agent is or may be resistant to approved and available alternative products.

To: i-node who wrote (754508)	12/30/2021 10:25:04 PM
From: Hugh Bett	10 Recommendations Recommended By Alan Smithee i-node isopatch kckip locogringo and 5 more members Read Replies (1) \| Respond to of 794008

You got it. That is why the ploy to demonize them by the media, politicians and bureaucrats who are in big pharma's back pocket.